Boston Scientific completes enrollment for aortic valve trial; Diagnostics startup Aggredyne raises $3M;

@FierceMedDev: 1,500 new construction jobs as IDA-backed investments ramp up--via SiliconRepublic. News | Follow @FierceMedDev

> Boston Scientific ($BSX) has completed enrollment for its REPRISE I trial, which is evaluating the safety of its Lotus aortic valve system. Release

> Diagnostics startup Aggredyne has raised $3 million in a Series A convertible preferred stock financing round. The company will use the money to add staff and gear up for a 510(k) filing for its lead product. Release

> Additional diagnostics tests are needed to help differentiate Alzheimer's disease cases with mixed pathology, University of Pennsylvania scientists have discovered. Release

> Delcath Systems ($DCTH), a specialty medical device and pharmaceutical company focused on cancer treatment, has closed a $20 million line of credit with Silicon Valley Bank to support growth and product development. Release

> Wakefield, MA-based ActiViews has gained 510(k) clearance for its flagship product, a needle guidance system designed for such CT-guided interventional procedures as biopsies and ablations.  Release

Biotech News

@FierceBiotech: Survey: Pharma lags peers in gaining trust via social media. Article | Follow @FierceBiotech

@JohnCFierce: Biota (Australia) to merge into U.S. biotech Nabi and move to U.S. Release | Follow @JohnCFierce

@RyanMFierce: Nice visualization of biotech VC trends dating back to '95. Graphics | Follow @RyanMFierce

> AstraZeneca reels in promising PhIII gout drug in $1.26B Ardea buyout. More

> Biotech VC deals, dollars shrivel in Q1 as devices see an upturn. Report

> Pike picked to sit at Quintiles peak. Item

Pharma News

@FiercePharma: Will lame-duck Congress go after pharma's advertising deduction? Ad lobbyists keeping an eye--AdAge. More | Follow @FiercePharma

> Amylin's up for bid. Who'll step in line? Article

> Pfizer gets $11.85B in nutrition sale to Nestlé. Item

> China sweeps up dozens in whirlwind drug-capsule probe. Report

> Novartis blueprints $550M Swiss drug plant after layoffs backlash. Story

> FDA prioritizes post-marketing drug safety, report says. Report

Biotech IT News

> NextBio moves genetic analysis software into clinical R&D territory. News

> Survey: Pharma lags peers in gaining trust via social media. More

> GAO report: FDA's IT modernization 'in jeopardy'. Story

> Google VC fuels Series A round for pharma software startup. Article

And Finally... The FDA is warning that consumer products using nanotechnology, such as skin creams, may require additional safety tests. Story

Suggested Articles

Longitude Capital invests in what its founders call “transformative healthcare companies," working in areas they hope will increase quality of life.

The FDA launched a center of excellence to oversee digital health products such as smartphone apps, wearable devices and software-based treatments.

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.